Viral hepatitis and haemophilia

Area of Science:

• Hematology
• Hepatology
• Virology

Background:

• Clotting factor concentrate therapy has revolutionized hemophilia management.
• Pre-1980s treatments lacked effective viral sterilization, leading to high rates of viral hepatitis transmission.
• Many hemophilia patients treated before the 1980s exhibit chronic liver disease, likely from non-A, non-B hepatitis agents.

Purpose of the Study:

• To review the impact of historical clotting factor concentrate therapy on viral hepatitis transmission in hemophilia patients.
• To discuss the pathogenesis of chronic liver disease in this population.
• To highlight current and future therapeutic strategies for viral infections in hemophilia.

Main Methods:

• Literature review of studies on hemophilia treatment, viral hepatitis transmission, and liver disease.
• Analysis of viral interactions, including hepatotropic agents and HIV, in hemophiliacs.
• Evaluation of therapeutic interventions like interferon and vaccination.

Main Results:

• Early clotting factor concentrates were associated with near-certain transmission of viral hepatitis.
• Non-A, non-B viral agents are implicated as primary causes of progressive liver disease in treated hemophiliacs.
• Complex viral interactions and atypical immune responses are observed in hemophiliacs with co-infections.

Conclusions:

• While modern therapies have improved hemophilia care, historical treatments caused significant liver disease.
• Interferon shows promise for treating viral hepatitis in hemophilia.
• Hepatitis B vaccination is crucial for hemophilia patients without existing immunity.